A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome - Beyond the Abstract
Interstitial cystitis (IC) is a chronic, disabling bladder disease with an uncertain etiology and a lack of effective treatments. There is evidence that IC may be an autoimmune disease. This study demonstrated that half the women with IC, who had not improved with any current therapies, had significant improvement in their symptoms with a medication used to treat autoimmune diseases. A multi-center trial to replicate my results is planned.
Written by: Philip Bosch, MD, Department of Urology, UC San Diego Medical Center, San Diego, CA, USA; Department of Urology, Palomar Medical Center, Escondido, CA, USA